Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pamiparib by BeiGene for Glioblastoma Multiforme (GBM): Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Pamiparib by BeiGene for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...
Pamiparib by BeiGene for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). According to...
Pamiparib by BeiGene for Peritoneal Cancer: Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
Pamiparib by BeiGene for Fallopian Tube Cancer: Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
Pamiparib by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Pamiparib by BeiGene for Endometrial Cancer: Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Pamiparib by BeiGene for Ovarian Cancer: Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...